vs
Varex Imaging Corp（VREX）与维谛技术（VRT）财务数据对比。点击上方公司名可切换其他公司
维谛技术的季度营收约是Varex Imaging Corp的12.6倍（$2.6B vs $209.6M）。维谛技术净利率更高（14.7% vs 1.1%，领先13.6%）。维谛技术同比增速更快（30.1% vs 4.9%）。维谛技术自由现金流更多（$652.8M vs $-26.8M）。过去两年维谛技术的营收复合增速更高（16.5% vs 0.8%）
Varex Imaging是全球知名的影像组件及解决方案供应商，核心产品涵盖X射线管、数字平板探测器和图像处理软件，广泛应用于医疗诊断、放射肿瘤治疗及工业无损检测等领域，客户覆盖全球主要市场。
维谛技术（Vertiv）是一家美国跨国企业，专注于为数据中心、通信网络、商业及工业场景提供关键基础设施及配套服务，旗下方案可有效保障各行业客户关键业务系统的稳定高效运行。
VREX vs VRT — 直观对比
营收规模更大
VRT
是对方的12.6倍
$209.6M
营收增速更快
VRT
高出25.2%
4.9%
净利率更高
VRT
高出13.6%
1.1%
自由现金流更多
VRT
多$679.6M
$-26.8M
两年增速更快
VRT
近两年复合增速
0.8%
损益表 — Q1 2026 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $209.6M | $2.6B |
| 净利润 | $2.3M | $390.1M |
| 毛利率 | 33.3% | 37.7% |
| 营业利润率 | 7.3% | — |
| 净利率 | 1.1% | 14.7% |
| 营收同比 | 4.9% | 30.1% |
| 净利润同比 | 866.7% | 137.1% |
| 每股收益（稀释后） | $0.05 | $0.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收VREXVRT
| Q1 26 | $209.6M | $2.6B | ||
| Q4 25 | $228.9M | $2.9B | ||
| Q3 25 | $203.0M | $2.7B | ||
| Q2 25 | $212.9M | $2.6B | ||
| Q1 25 | $199.8M | $2.0B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | $205.7M | $2.1B | ||
| Q2 24 | $209.1M | $2.0B |
净利润VREXVRT
| Q1 26 | $2.3M | $390.1M | ||
| Q4 25 | $12.2M | $445.6M | ||
| Q3 25 | $-89.1M | $398.5M | ||
| Q2 25 | $6.9M | $324.2M | ||
| Q1 25 | $-300.0K | $164.5M | ||
| Q4 24 | — | $147.0M | ||
| Q3 24 | $-51.1M | $176.6M | ||
| Q2 24 | $1.4M | $178.1M |
毛利率VREXVRT
| Q1 26 | 33.3% | 37.7% | ||
| Q4 25 | 34.0% | 38.9% | ||
| Q3 25 | 33.3% | 37.8% | ||
| Q2 25 | 36.0% | 34.0% | ||
| Q1 25 | 34.3% | 33.7% | ||
| Q4 24 | — | 37.1% | ||
| Q3 24 | 32.6% | 36.5% | ||
| Q2 24 | 32.0% | 38.0% |
营业利润率VREXVRT
| Q1 26 | 7.3% | — | ||
| Q4 25 | 8.6% | 20.1% | ||
| Q3 25 | -39.8% | 19.3% | ||
| Q2 25 | 10.4% | 16.8% | ||
| Q1 25 | 5.6% | 14.3% | ||
| Q4 24 | — | 19.5% | ||
| Q3 24 | 5.3% | 17.9% | ||
| Q2 24 | 4.4% | 17.2% |
净利率VREXVRT
| Q1 26 | 1.1% | 14.7% | ||
| Q4 25 | 5.3% | 15.5% | ||
| Q3 25 | -43.9% | 14.9% | ||
| Q2 25 | 3.2% | 12.3% | ||
| Q1 25 | -0.2% | 8.1% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -24.8% | 8.5% | ||
| Q2 24 | 0.7% | 9.1% |
每股收益（稀释后）VREXVRT
| Q1 26 | $0.05 | $0.99 | ||
| Q4 25 | $0.29 | $1.14 | ||
| Q3 25 | $-2.15 | $1.02 | ||
| Q2 25 | $0.17 | $0.83 | ||
| Q1 25 | $-0.01 | $0.42 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $-1.25 | $0.46 | ||
| Q2 24 | $0.03 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $125.6M | $2.5B |
| 总债务越低越好 | $367.6M | $0 |
| 股东权益账面价值 | $476.9M | $4.2B |
| 总资产 | $1.1B | $13.4B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资VREXVRT
| Q1 26 | $125.6M | $2.5B | ||
| Q4 25 | $155.1M | $1.7B | ||
| Q3 25 | $152.6M | $1.4B | ||
| Q2 25 | $223.0M | $1.6B | ||
| Q1 25 | $212.6M | $1.5B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $200.5M | $908.7M | ||
| Q2 24 | $190.0M | $579.7M |
总债务VREXVRT
| Q1 26 | $367.6M | $0 | ||
| Q4 25 | $367.5M | $2.9B | ||
| Q3 25 | $367.5M | $2.9B | ||
| Q2 25 | $567.2M | $2.9B | ||
| Q1 25 | $567.0M | $2.9B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $443.4M | $2.9B | ||
| Q2 24 | $443.1M | $2.9B |
股东权益VREXVRT
| Q1 26 | $476.9M | $4.2B | ||
| Q4 25 | $472.6M | $3.9B | ||
| Q3 25 | $455.3M | $3.5B | ||
| Q2 25 | $549.7M | $3.1B | ||
| Q1 25 | $540.2M | $2.7B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | $529.1M | $1.8B | ||
| Q2 24 | $581.2M | $1.5B |
总资产VREXVRT
| Q1 26 | $1.1B | $13.4B | ||
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $1.1B | $10.8B | ||
| Q2 25 | $1.4B | $10.4B | ||
| Q1 25 | $1.3B | $9.5B | ||
| Q4 24 | — | $9.1B | ||
| Q3 24 | $1.2B | $8.9B | ||
| Q2 24 | $1.3B | $8.1B |
负债/权益比VREXVRT
| Q1 26 | 0.77× | 0.00× | ||
| Q4 25 | 0.78× | 0.74× | ||
| Q3 25 | 0.81× | 0.83× | ||
| Q2 25 | 1.03× | 0.93× | ||
| Q1 25 | 1.05× | 1.10× | ||
| Q4 24 | — | 1.20× | ||
| Q3 24 | 0.84× | 1.62× | ||
| Q2 24 | 0.76× | 1.91× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.1M | — |
| 自由现金流经营现金流 - 资本支出 | $-26.8M | $652.8M |
| 自由现金流率自由现金流/营收 | -12.8% | 24.6% |
| 资本支出强度资本支出/营收 | 5.1% | 4.2% |
| 现金转化率经营现金流/净利润 | -7.00× | — |
| 过去12个月自由现金流最近4个季度 | $-13.3M | $2.3B |
8季度趋势，按日历期对齐
经营现金流VREXVRT
| Q1 26 | $-16.1M | — | ||
| Q4 25 | $7.9M | $978.9M | ||
| Q3 25 | $7.7M | $508.7M | ||
| Q2 25 | $16.6M | $322.9M | ||
| Q1 25 | $9.5M | $303.3M | ||
| Q4 24 | — | $425.2M | ||
| Q3 24 | $25.9M | $378.2M | ||
| Q2 24 | $8.0M | $378.4M |
自由现金流VREXVRT
| Q1 26 | $-26.8M | $652.8M | ||
| Q4 25 | $2.3M | $885.6M | ||
| Q3 25 | $1.4M | $463.5M | ||
| Q2 25 | $9.8M | $277.9M | ||
| Q1 25 | $5.3M | $266.8M | ||
| Q4 24 | — | $364.5M | ||
| Q3 24 | $19.9M | $341.8M | ||
| Q2 24 | $3.3M | $344.3M |
自由现金流率VREXVRT
| Q1 26 | -12.8% | 24.6% | ||
| Q4 25 | 1.0% | 30.8% | ||
| Q3 25 | 0.7% | 17.3% | ||
| Q2 25 | 4.6% | 10.5% | ||
| Q1 25 | 2.7% | 13.1% | ||
| Q4 24 | — | 15.5% | ||
| Q3 24 | 9.7% | 16.5% | ||
| Q2 24 | 1.6% | 17.6% |
资本支出强度VREXVRT
| Q1 26 | 5.1% | 4.2% | ||
| Q4 25 | 2.4% | 3.2% | ||
| Q3 25 | 3.1% | 1.7% | ||
| Q2 25 | 3.2% | 1.7% | ||
| Q1 25 | 2.1% | 1.8% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 2.9% | 1.8% | ||
| Q2 24 | 2.2% | 1.7% |
现金转化率VREXVRT
| Q1 26 | -7.00× | — | ||
| Q4 25 | 0.65× | 2.20× | ||
| Q3 25 | — | 1.28× | ||
| Q2 25 | 2.41× | 1.00× | ||
| Q1 25 | — | 1.84× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | 2.14× | ||
| Q2 24 | 5.71× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
VRT
暂无分部数据
